iNOS remained a significant predictor of outcome in the multivariable analysis after adjustment for age at diagnosis, neoadjuvant therapy, tumor grade and histological subtype, with low levels of iNOS associated a breast cancer specific free survival HR of 5.0 (95% Confidence Interval (CI) 1.16-21.94; p=0.031), while intermediate levels are associated with a HR of 7.2 (95% CI 1.60-32.34; p=0.010) in the multivariable analysis (Table 2). The gene discussed is NOS2; the disease is breast cancer.